Schizophrenia Research
Volume 120, Issue 1 , Pages 16-22 , July 2010

The psychosis risk syndrome and its proposed inclusion in the DSM-V: A risk–benefit analysis

  • Cheryl M. Corcoran

      Affiliations

    • Department of Psychiatry, New York State Psychiatric Institute at Columbia University, 1051 Riverside Drive, New York, NY, 10032, USA
    • Corresponding Author InformationCorresponding author. NYSPI Unit 55, 1051 Riverside Drive, New York, NY, 10032, USA. Tel.: +1 212 543 6177; fax: +1 212 543 6176.
    • ,
  • Michael B. First

      Affiliations

    • Department of Psychiatry, New York State Psychiatric Institute at Columbia University, 1051 Riverside Drive, New York, NY, 10032, USA
    • ,
  • Barbara Cornblatt

      Affiliations

    • Psychiatry Research, Zucker Hillside Hospital, North-Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA

Received 5 February 2010 ,Accepted 12 March 2010.

References 

  1. Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, et al. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr. Bull. 2007;33(3):665–672
  2. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol. Psychiatry. 2007;61(4):551–553
  3. Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders. A randomized, placebo-controlled trial. Arch. Gen. Psychiatry. 2010;67(2):146–154
  4. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am. J. Psychiatry. 2005;162(1):71–78
  5. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry. 2008;65(1):28–37
  6. Corcoran C, Malaspina D, Hercher L. Prodromal interventions for schizophrenia vulnerability: the risks of being “at risk”. Schizophr. Res. 2005;73(2–3):173–184
  7. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr. Bull. 2003;29(4):633–651
  8. Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J. Clin. Psychiatry. 2007;68(4):546–557
  9. Done DJ, Crow TJ, Johnstone EC, Sacker A. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ. 1994;309(6956):699–703
  10. Fish B, Marcus J, Hans SL, Auerbach JG, Perdue S. Infants at risk for schizophrenia: sequelae of a genetic neurointegrative defect. A review and replication analysis of pandysmaturation in the Jerusalem Infant Development Study. Arch. Gen. Psychiatry. 1992;49(3):221–235
  11. Gold J. Late luteal phase dysphoric disorder: a final overview. In:  Widiger T,  Frances A,  Pincus H,  Ross R,  First M,  Davis W editor. DSM-IV Sourcebook. Volume 4:Washington DC: American Psychiatric Association; 1998;p. 1035–1046
  12. Hafner H, An der Heiden W, Behrens S, Gattaz WF, Hambrecht M, Loffler W, et al. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr. Bull. 1998;24(1):99–113
  13. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994;344(8934):1398–1402
  14. Larsen TK. The transition from premorbid period to psychosis: how can it be described?. Acta Psychiatr. Scand. 2007;106(suppl):10–11
  15. Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L, et al. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol. Psychiatry. 2006;59(9):863–871
  16. Lieberman JA, Corcoran C. The impossible dream: can psychiatry prevent psychosis?. Early Interv. Psychiatry. 2007;1(3):219–221
  17. Link BG, Phelan JC. Conceptualizing stigma. Annu. Rev. Sociol. 2001;27(1):363–385
  18. Link BG, Cullen FT, Struening E, Shrout PE, Dohrenwend BP. A modified labeling theory approach to mental disorders: an empirical assessment. Am. Sociol. Rev. 1989;54(3):400–423
  19. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. State and trait predictors of transition to first episode psychosis among individuals with at risk mental states. Schizophr. Res. 2004;71:227–237
  20. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry. 2006;163(5):790–799
  21. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry. 2002;59(10):921–928
  22. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003;29(4):703–715
  23. Morrison AP, Bentall RP, French P, Walford L, Kilcommons A, Knight A, et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals: study design and interim analysis of transition rate and psychological risk factors. Br. J. Psychiatry. 2002;181(suppl 43):s78–s84
  24. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry. 2004;185(4):291–297
  25. Olin S-CS, Mednick SA, Cannon T, Jacobsen B, Parnas J, Schulsinger F, et al. School teacher ratings predictive of psychiatric outcome 25years later. Br. J. Psychiatry. 1998;172(Suppl 33):7–13
  26. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch. Gen. Psychiatry. 2000;57(11):1053–1058
  27. Schobel SA, Lewandowski NM, Corcoran CM, Moore H, Brown T, Malaspina D, et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch. Gen. Psychiatry. 2009;66(9):938–946
  28. Severino S. Premenstrual dysphoric disorder: controversies surrounding the diagnosis. Harv. Rev. Psychiatry. 1996;3(5):293–295
  29. Spitzer R, Severino S, Williams J, Parry B. Late luteal phase dysphoric disorder and DSM-III-R. Am. J. Psychiatry. 1989;146(7):892–897
  30. Tarrant CJ, Jones PB. Precursors to schizophrenia: do biological markers have specificity?. Can. J. Psychiatry. 1999;44(4):335–349
  31. Van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban–rural comparison. Arch. Gen. Psychiatry. 2001;58(7):663–668
  32. Verdoux H, van Os J. Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophr. Res. 2002;54(1–2):59–65
  33. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847
  34. Wong C, Davidson L, Anglin D, Link B, Gerson R, Malaspina D, et al. Stigma in families of individuals in early stages of psychotic illness: family stigma and early psychosis. Early Interv. Psychiatry. 2009;3(2):108–115
  35. Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, et al. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br. J. Psychiatry. 2007;51:s96–s101(Suppl)
  36. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr. Bull. 2009;35(5):894–908
  37. Yang, L.H., Wonpat-Borja, A.J., Opler, M., Corcoran, C., 2010. Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: An empirical question. Schizophr. Res. 120, 42–48 (this issue).
  38. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, et al. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr. Res. 2003;60(1):21–32
  39. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust. NZ J. Psychiatry. 2005;39(11–12):964–971
  40. Yung AR, Yuen HP, Berger G, Francey S, Hung T-C, Nelson B, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?. Schizophr. Bull. 2007;33(3):673–681
  41. Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, Killackey E, et al. Validation of “prodromal” criteria to detect individuals at ultra high risk of psychosis: 2year follow-up. Schizophr. Res. 2008;105(1–3):10–17
  42. Yung AR, Nelson B, Baker K, Buckby JA, Baksheev G, Cosgrave EM. Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia. Aust. NZ J. Psychiatry. 2009;43(2):118–128

PII: S0920-9964(10)01188-6

doi: 10.1016/j.schres.2010.03.018

Schizophrenia Research
Volume 120, Issue 1 , Pages 16-22 , July 2010

Article Tools